Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy?
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In the U.K., people with diabetes are typically screened for retinopathy annually. However, diabetic retinopathy sometimes has a slow progression rate. We developed a simulation model to predict the likely impact of screening patients with type 2 diabetes, who have not been diagnosed with diabetic retinopathy, every 2 years rather than annually. We aimed to assess whether or not such a policy would increase the proportion of patients who developed retinopathy-mediated vision loss compared with the current policy, along with the potential cost savings that could be achieved. RESEARCH DESIGN AND METHODS: We developed a model that simulates the progression of retinopathy in type 2 diabetic patients, and the screening of these patients, to predict rates of retinopathy-mediated vision loss. We populated the model with data obtained from a National Health Service Foundation Trust. We generated comparative 15-year forecasts to assess the differences between the current and proposed screening policies. RESULTS: The simulation model predicts that implementing a 2-year screening interval for type 2 diabetic patients without evidence of diabetic retinopathy does not increase their risk of vision loss. Furthermore, we predict that this policy could reduce screening costs by ∼25%. CONCLUSIONS: Screening people with type 2 diabetes, who have not yet developed retinopathy, every 2 years, rather than annually, is a safe and cost-effective strategy. Our findings support those of other studies, and we therefore recommend a review of the current National Institute for Health and Clinical Excellence (NICE) guidelines for diabetic retinopathy screening implemented in the U.K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial intelligence approaches to screening for diabetic retinopathy have progressed to the point of utility and cost-effectiveness.508–513”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [510]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
The Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., & DeMets, D. L. (1987) · Ophthalmology · doi:10.1016/s0161-6420(87)33525-0 · Cited by 1,249
Fong, D. S., Aiello, L., Gardner, T. W., King, G. L., Blankenship, G., Cavallerano, J. D., Ferris, F. L., Klein, R., & for the American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s84 · Cited by 1,082
Stratton, I. M., Kohner, E. M., Aldington, S. J., Turner, R. C., Holman, R. R., Manley, S. E., & Matthews, D. R. (2001) · Diabetologia · doi:10.1007/s001250051594 · Cited by 1,019
Kohner, E. M. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.3.297 · Cited by 474
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010243030 · Cited by 470
Davis, M. D., Fisher, M. R., Gangnon, R. E., Barton, F. B., Aiello, L. M., Chew, E. Y., Ferris, F. L., & Knatterud, G. L. (1998) · PubMed · Cited by 455
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010250031 · Cited by 361 · cited 2×
“We conducted an extensive search of papers published after the Wisconsin Epidemiologic Study of Diabetic Retinopathy (12), upon which the POST study was based (1,11), to see if there had been any newer, but similar, large-scale cohort studies that drew from a wide diabetic population and looked at the progression of d…”
MethodResultTrends in the prevalence and incidence of diabetes in the UK: 1996–2005
González, E. L. M., Johansson, S., Wallander, M.-A., & Rodríguez, L. A. G. (2009) · Journal of Epidemiology and Community Health · doi:10.1136/jech.2008.080382 · Cited by 297 · cited 1×
“42/ 1,000 person-years in the model as an initial estimate (17) and increased this by 4.”
BackgroundYounis, N., Broadbent, D. M., Vora, J. P., & Harding, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12267-2 · Cited by 289
Cited by
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
van der Heijden, A. A., Abramoff, M. D., Verbraak, F., van Hecke, M. V., Liem, A., & Nijpels, G. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13613 · Cited by 296
“Screening for DR has proven to be effective in the prevention of blindness, and some national health authorities and most professional organizations have adopted an annual or biennial screening programme which is usually integrated within regular diabetes care (Olafsdottir & Stefansson 2007; Rodbard et al. 2007; Scanl…”
BackgroundLearning ensemble classifiers for diabetic retinopathy assessment
Saleh, E., Błaszczyński, J., Moreno, A., Valls, A., Romero-Aroca, P., de la Riva-Fernández, S., & Słowiński, R. (2018) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2017.09.006 · Cited by 97
Metadata
- Authors
- Chalk, D., Pitt, M., Vaidya, B., & Stein, K.
- Affiliations
- University of Exeter (GB)
- Royal Devon & Exeter NHS Foundation Trust (GB)
- Corresponding author
- Chalk, Daniel
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-07-14
- Volume
- 35
- Issue
- 8
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3402259
- OpenAlex
- W2121408450
- Cited by
- 48
- References
- 28
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 6 · 2018: 3 · 2017: 6 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 5
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by-nc-nd)
- Open Research Exeter (University of Exeter) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy screening, type 2 diabetes, screening frequency, retinopathy progression, vision loss, cost-effectiveness, computer simulation, NICE guidelines, National Health Service
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Humans, Male, Mass Screening, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy? https://app.cochat.ai/papers/10.2337/dc11-2282
- The paper
- Chalk, D., Pitt, M., Vaidya, B., & Stein, K. (2012). Can the Retinal Screening Interval Be Safely Increased to 2 Years for Type 2 Diabetic Patients Without Retinopathy? Diabetes Care. https://doi.org/10.2337/dc11-2282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.